CRBU News and Press, Caribou Biosciences Inc. From 03/21/24

2024-03-21 11:53:17 ET More on S&P 500 Index: Chairman Powell Hits A Grand Slam Home Run Despite What The Fed Says, The Policy Is Still 'Higher-For-Longer' The Fed Is More Dovish Than The Market Anticipates 32 “Breakthroughs” stocks by BofA ...

2024-03-12 12:37:04 ET Shares of Caribou Biosciences (NASDAQ: CRBU) were crashing 19.7% lower as of 11:13 a.m. ET on Tuesday. The big sell-off came after the biotech provided its fourth-quarter update on Monday. Caribou reported fourth-quarter licensing revenue of $3.6 million a...

2024-03-12 12:21:11 ET More on Mid-day movers & stocks. FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes Lexaria slips ...

2024-03-11 16:52:28 ET More on Caribou Bioscience Caribou Biosciences: Under The Radar With Catalysts Approaching Biotech And Pharma Diversification Pays Off Seeking Alpha’s Quant Rating on Caribou Bioscience Historical earnings data for Caribou Biosci...

-- 30 th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1 st patient dosed in CB-012 AMpLify Phase 1 trial for patients with r/r AML -- -- $372.4 million in cash, cash equ...

BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or ...

2024-02-26 06:45:00 ET The hunt for winning biotech stocks never truly ends, and it's easy to see why. Over the last five years, shares of the gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) are up by 146%, easily topping the market's return of 94%. The company recently succ...

2024-02-15 13:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-05 00:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-01 08:50:44 ET Summary CRBU has provided regulatory and clinical updates in the past couple of months, but hasn't rallied quite like other biotech names. CRBU achieved alignment with the FDA on the comparator arm for its pivotal study of CB-010, and confirmed further data ...